166 related articles for article (PubMed ID: 37855094)
1. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
[TBL] [Abstract][Full Text] [Related]
2. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
[TBL] [Abstract][Full Text] [Related]
3. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
4. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
6. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
[TBL] [Abstract][Full Text] [Related]
7. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS
Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
[TBL] [Abstract][Full Text] [Related]
9. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
10. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
[TBL] [Abstract][Full Text] [Related]
11. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
12. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
Ustianowski A
Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
[TBL] [Abstract][Full Text] [Related]
13. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
[TBL] [Abstract][Full Text] [Related]
14. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
[No Abstract] [Full Text] [Related]
15. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
[TBL] [Abstract][Full Text] [Related]
18. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL
Front Immunol; 2023; 14():1259725. PubMed ID: 37928549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
